Classification and Diagnostic Criteria

CDCES Certified Diabetes Care and Education Specialist

Track your progress as you read

Finished sections get a check mark.

1 Introduction & the CDCES Exam

About the CDCES Credential & Current Exam Facts The July 2024 Exam Content Outline & Domain Weights The ADCES7 Self-Care Behaviors Framework

2 Pathophysiology, Classification & Diagnosis

Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM Classification and Diagnostic Criteria Risk Factors and Primary Prevention Treatment Goals and Glycemic Targets

3 Assessment: History, Physical & Data

Health History & Diabetes-Specific Physical Assessment Interpreting Diabetes Measures & Laboratory Data Social Determinants of Health & Psychosocial Wellbeing

4 Assessing Self-Management & Learning

Assessing Self-Management Behaviors & Knowledge Assessing Technology Use, Problem-Solving & Risk-Reduction Behaviors Assessing Learning: Goals, Readiness to Change & Literacy Learning Considerations & Barriers

5 Developing the Education & Care Plan

Developing the Individualized Education/Care Plan Instructional Methods & Person-Centered Teaching Strategies SMART Goals, Behavior-Change Theory & Motivational Interviewing

6 Nutrition Therapy

Nutrition Recommendations & Eating Patterns Carbohydrate Counting & Insulin-Food Timing Fats, Protein, Alcohol & Dietary Supplements Food Labels, Weight Management & Special Nutrition Considerations

7 Physical Activity

Physical Activity Recommendations, Benefits, Challenges & Safety Activity Planning with FITT and Adjusting for Planned & Unplanned Activity

8 Pharmacologic Therapy

Insulin — Types, Pharmacokinetics & Delivery Systems Non-Insulin Glucose-Lowering Agents Guideline-Based Medication Selection Medication Titration & Immunizations for People with Diabetes

9 Monitoring

Glucose Monitoring: SMBG, CGM & Time in Range A1C and Ketone Monitoring Cardiometabolic and Organ System Monitoring

10 Acute Complications

Hypoglycemia Hyperglycemia, DKA, and HHS

11 Chronic Complications

Screening Schedules and Microvascular Disease Macrovascular Disease and Lower-Extremity Foot Care Infections, Dental Disease, Sexual Dysfunction, and Other Comorbidities

12 Special Situations & Populations

Sick-Day Management, Surgery, Travel & Emergency Preparedness Special Populations Across the Lifespan Preconception, Pregnancy, Postpartum & Gestational Diabetes Daily Living, Psychosocial Wellbeing & Safety

13 Evaluation & Documentation

Evaluating Intervention Effectiveness & Outcomes Documentation, Plan Revision & Referral

14 Standards, Guidelines & Professional Practice

National Standards for DSMES and the National DPP Applying Evidence-Based Practice Guidelines Population Health, Health Equity & Advocacy

Classification and Diagnostic Criteria

Key Takeaways Explain This Topic AI

The ADA diagnoses diabetes with an A1C of 6.5% or higher, a fasting plasma glucose of 126 mg/dL or higher, a 2-hour 75-g OGTT glucose of 200 mg/dL or higher, or a random glucose of 200 mg/dL or higher with classic hyperglycemia symptoms.

Prediabetes is defined by an A1C of 5.7%-6.4%, a fasting glucose of 100-125 mg/dL (IFG), or a 2-hour OGTT glucose of 140-199 mg/dL (IGT).

LADA is slow-onset autoimmune diabetes presenting in adulthood, usually GAD65-antibody positive, while MODY is monogenic diabetes with autosomal dominant inheritance and onset typically before age 25.

The one-step gestational diabetes approach diagnoses GDM from a 75-g OGTT if any one value meets fasting 92 mg/dL, 1-hour 180 mg/dL, or 2-hour 153 mg/dL or higher.

The two-step gestational diabetes approach requires at least 2 of 4 values on a 100-g OGTT (fasting 95, 1-hour 180, 2-hour 155, 3-hour 140 mg/dL or higher) to diagnose GDM after a positive 50-g glucose challenge test.

Last updated: July 2026

Diagnostic Criteria for Diabetes

The ADA Standards of Care in Diabetes diagnoses diabetes using any one of four criteria; in the absence of unequivocal hyperglycemia, the result should be confirmed by repeat testing, ideally with the same test on a separate day.

• Test Diagnostic Threshold
• A1C ≥6.5% (≥48 mmol/mol)
• Fasting plasma glucose (FPG) ≥126 mg/dL (≥7.0 mmol/L); no caloric intake for at least 8 hours
• 2-hour plasma glucose, 75-g OGTT ≥200 mg/dL (≥11.1 mmol/L)

Random plasma glucose ≥200 mg/dL plus classic hyperglycemia symptoms (polyuria, polydipsia, unexplained weight loss) or hyperglycemic crisis

If two different tests from the same sample (for example, A1C and FPG) are both above threshold, the diagnosis is confirmed without further repeat testing. If two different tests are discordant, the test that is above the diagnostic threshold should be repeated. A1C can be unreliable in conditions that affect red-cell turnover — hemolytic anemia, recent blood loss or transfusion, hemoglobinopathies, and pregnancy — in which case glucose-based criteria should be used instead of A1C.

Prediabetes

Prediabetes is defined by meeting any of the following; none requires symptoms:

• Test Range
• A1C 5.7%-6.4%
• Impaired fasting glucose (IFG) FPG 100-125 mg/dL
• Impaired glucose tolerance (IGT) 2-hour plasma glucose, 75-g OGTT, 140-199 mg/dL

A person can meet more than one prediabetes criterion at once, for example both IFG and IGT. Meeting multiple criteria does not change the diagnosis but does correlate with a higher risk of progressing to type 2 diabetes and often prompts more assertive lifestyle counseling and National DPP referral, covered in section 2.3.

Classifying the Types

Type 1 diabetes — autoimmune beta-cell destruction; absolute insulin deficiency; typically autoantibody-positive (GAD65, IA-2, IAA, ZnT8)

Type 2 diabetes — insulin resistance plus relative, progressive insulin deficiency; the most common form

LADA (Latent Autoimmune Diabetes in Adults) , sometimes called "type 1.5" — slower-onset autoimmune beta-cell destruction presenting in adulthood; usually GAD65-antibody positive; may be manageable without insulin at diagnosis but progresses to insulin dependence as autoimmune destruction continues

MODY (Maturity-Onset Diabetes of the Young) — monogenic, single-gene defect inherited in an autosomal dominant pattern; onset typically before age 25 with a strong multigenerational family history; the most common subtypes are GCK-MODY , which is mild and stable and often needs no pharmacologic treatment, and HNF1A-MODY , which is progressive and characteristically sulfonylurea-sensitive

Secondary diabetes — hyperglycemia caused by another condition or agent: pancreatic disease (pancreatitis, cystic fibrosis-related diabetes, pancreatectomy, hemochromatosis), endocrinopathies (Cushing syndrome, acromegaly, pheochromocytoma), or drug- or chemical-induced hyperglycemia (glucocorticoids, atypical antipsychotics, post-transplant immunosuppressants such as tacrolimus)

Diabetes diagnosed in the first trimester of pregnancy, or before 24 weeks' gestation, using the standard non-pregnancy criteria above is classified as overt or pregestational diabetes , not gestational diabetes — an important distinction for both risk stratification and postpartum follow-up.

Distinguishing type 1 from type 2 diabetes at diagnosis relies on clinical context plus targeted testing: a low or undetectable C-peptide level indicates minimal endogenous insulin production, consistent with type 1 diabetes or long-standing type 2 diabetes, while a normal-to-high C-peptide alongside obesity, insulin resistance, and negative autoantibodies points to type 2 diabetes. Islet autoantibody panels (GAD65, IA-2, IAA, ZnT8) help identify type 1 diabetes and LADA when the clinical picture is ambiguous, such as an adult presenting with a normal BMI, rapid progression to insulin dependence, or a personal or family history of other autoimmune disease.

Gestational Diabetes Mellitus: One-Step vs. Two-Step Screening

Gestational diabetes mellitus (GDM) is screened between 24 and 28 weeks' gestation in people not already known to have diabetes, earlier if risk factors suggest pre-existing, undiagnosed diabetes. The ADA accepts either of two screening strategies; institutions choose one.

One-step approach (IADPSG criteria): a fasting 75-g OGTT; GDM is diagnosed if any one value meets or exceeds:

• Timepoint Threshold
• Fasting ≥92 mg/dL
• 1-hour ≥180 mg/dL
• 2-hour ≥153 mg/dL

Two-step approach: Step 1 is a non-fasting 50-g glucose challenge test (GCT) ; a 1-hour value above the institution's chosen cutoff, commonly in the 130-140 mg/dL range, is a positive screen requiring Step 2, the diagnostic 100-g OGTT performed fasting. GDM is diagnosed if at least 2 of the 4 values meet or exceed the Carpenter-Coustan thresholds:

• Timepoint Threshold
• Fasting ≥95 mg/dL
• 1-hour ≥180 mg/dL
• 2-hour ≥155 mg/dL
• 3-hour ≥140 mg/dL

The one-step approach diagnoses more people with GDM, since lower thresholds and a single abnormal value both increase sensitivity, and reflects the IADPSG framework the ADA endorses. The two-step approach remains widely used clinically in the United States and is endorsed by ACOG and an NIH consensus panel. A CDCES should be able to explain either pathway accurately to a person being screened, since the pathway used depends on the practice or institution, not on the person's individual risk.

Regardless of which screening pathway was used during pregnancy, everyone diagnosed with GDM should be tested for persistent diabetes with a 75-g OGTT at 4-12 weeks postpartum, applying the standard non-pregnancy diagnostic criteria from the top of this section rather than the pregnancy-specific gestational thresholds.